Related Experiment Video
Updated: Apr 5, 2026
Carotid Artery Infusions for Pharmacokinetic and Pharmacodynamic Analysis of Taxanes in Mice
Published on: October 27, 2014
Emerging Strategies and Challenges for Controlled Delivery of Taxanes: A Comprehensive Review
Mohit Mahajan, Rajneet Kaur Khurana, Nikhil Shri Sahajpal
1Department of Pharmaceutical Sciences, Guru Nanak Dev University, Amritsar [Punjab] 143 005 INDIA. subheetjain.pharm@gndu.ac.in.
Abstract:
Taxanes introduction in the mid 90 s leads to significant advancement as well as superlative improvement in the treatment of cancer. Since then, several strategies have been designed to enhance therapeutic potential of these agents by overcoming the limitations in drug delivery and pharmacokinetic constraints associated with conventional delivery. In this regard, controlled drug delivery systems for taxanes have contributed enormously by altering the pharmacokinetic profile, thus ultimately enhancing their therapeutic response. With their conferred stellar merits, controlled drug delivery systems have been able to surmount many of the challenges associated with conventional drug delivery systems. The altered absorption, resistance, low toxicity and cellular uptake profiles that lead to better safety from variegated carrier systems like nanocarriers, liposomes, solid lipid nanoparticles, nanoemulsions, nanocapsules, hydrogels and micelles for controlled delivery of taxanes call for an exhaustive review for future progressive work. Therefore, this review focuses on the altered pharmacokinetic, pharmacodynamic and toxicity patterns achieved from various controlled drug delivery approaches, with the latter half highlighting the clinical profile set ups and commercial aspects of controlled release drug delivery systems.
Insights
Controlled drug delivery systems significantly improve cancer treatment with taxanes by overcoming limitations. These advanced systems enhance drug absorption, reduce toxicity, and improve cellular uptake for better therapeutic outcomes.
Area of Science:
- Pharmacology and Pharmaceutical Sciences
- Oncology
- Biomedical Engineering
Background:
- Taxanes revolutionized cancer therapy in the mid-1990s, but conventional delivery methods present significant limitations.
- Challenges include pharmacokinetic constraints, drug resistance, and toxicity, hindering optimal therapeutic potential.
- Controlled drug delivery systems offer a promising avenue to enhance taxane efficacy and safety.
Purpose of the Study:
- To review the advancements in controlled drug delivery systems for taxanes.
- To analyze how these systems alter pharmacokinetic and pharmacodynamic profiles.
- To highlight improvements in toxicity, absorption, and cellular uptake, and discuss clinical and commercial aspects.
Main Methods:
- Comprehensive literature review of controlled drug delivery systems for taxanes.
- Analysis of various nanocarrier systems including liposomes, solid lipid nanoparticles, nanoemulsions, nanocapsules, hydrogels, and micelles.
- Evaluation of pharmacokinetic, pharmacodynamic, and toxicity data from existing studies.
Main Results:
- Controlled delivery systems significantly alter taxane absorption, resistance, and cellular uptake.
- Various carrier systems demonstrate improved safety profiles and enhanced therapeutic responses compared to conventional methods.
- Specific examples of nanocarriers show promise in overcoming delivery challenges.
Conclusions:
- Controlled drug delivery systems represent a significant advancement in optimizing taxane-based cancer therapy.
- These systems offer improved efficacy, reduced toxicity, and better patient outcomes.
- Further research into clinical applications and commercialization of these advanced delivery systems is warranted.
